Personalized rituximab for membranous nephropathy using AI
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests if an artificial intelligence tool can help doctors decide the best dose and timing of rituximab for people with a kidney condition called membranous nephropathy. It aims to improve treatment results and reduce side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have active membranous nephropathy with a positive test for anti-PLA2R1 antibodies (≥14 RU/ml)
- You have nephrotic syndrome (high protein in urine and low albumin in blood)
- Your kidney function is at least 30% of normal (eGFR > 30)
- You have not had rituximab or other immune-suppressing drugs in the last 6 months
- You are on a stable dose of blood pressure and water pill medications for at least 2 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how rituximab affects immune cells in people with a type of kidney disease called membranous nephropathy. By studying blood samples, the researchers hope to understand why some people respond better to treatment, which could help guide future care.
This trial tests a combination of two medications, rituximab and cyclosporine, for people with primary membranous nephropathy, a kidney disease that causes protein in the urine. The goal is to see if this combination can reduce protein loss and improve kidney function, potentially preserving kidney health.
This study tests whether adding belimumab to rituximab helps people with primary membranous nephropathy (a kidney disease) that has the right blood test marker and specific protein levels. The goal is to improve kidney outcomes and reduce disease activity while keeping treatment safe.
This study looks at blood and tissue samples from people with membranous nephropathy, a kidney disease, to find biological markers that predict whether rituximab, a treatment, will work. The goal is to understand why some patients do not respond, which could lead to better personalized treatment.
This trial tests a new drug called HLX79 (a human sialidase fusion protein) combined with rituximab, compared to a placebo, for people with active membranous nephropathy (a kidney disease). It aims to see if this combination can reduce protein in the urine and improve kidney function.
This trial looks at how people with primary membranous nephropathy (a kidney disease that causes swelling and protein in urine) do over time with their current treatment. It helps doctors understand which treatments work best, especially for those with severe protein loss.
Hear when a new Membranous Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.